SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Other Events
Item8.01.
| Other Events. |
On May1, 2017, Sunesis Pharmaceuticals, Inc. issued a press
release announcing the withdrawal of its European Marketing
Authorization Application for vosaroxin as a treatment for
relapsed/refractory acute myeloid leukemia. A copy of the press
release issued concerning the foregoing is filed herewith as
Exhibit 99.1 and is incorporated herein by reference.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit No. |
Description |
|
| 99.1 |
Press release, dated May 1, 2017, entitled Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML |
About SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration. SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Recent Trading Information
SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) closed its last trading session down -0.22 at 3.65 with 27,067 shares trading hands.
